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A B S T R A C T
Drug eluting stents (DES) have ushered in a new era in non-surgical coronary revas-
cularization with substantially reduced rates of restenosis, albeit at an increased ex-
pense for our health care system incurred by their higher cost compared to bare metal 
stents (BMS) and by a high demand of these devices by both physicians and patients. 
The risk of late thrombosis and other safety issues will need to be further investigated. 
The cost-effectiveness of DES depends on the features of the target population, the 
higher DES cost, any remaining safety issues and the specific treatment comparator 
(BMS, surgical or medical therapy). According to the data of economic analyses and 
clinical trials, DES will be reasonably cost-effective for a great percentage of patients 
and even cost saving for the subgroup of patients who are at high risk of clinical reste-
nosis with the conventional PCI techniques. The main limitation of wider application 
of DES in the daily interventional practice remains their high price, which if lowered 
in the future will broaden their target population in interventional cardiology.
Drug eluting stents (DES) represent one of the most innovative developments in 
interventional cardiology and the third (post balloon PTCA and metallic stent devel-
opment) blasting innovation, which determined a dramatic change in the treatment 
practice of coronary artery disease. It is widely known that the main drawback of 
non surgical treatment (percutaneous coronary intervention-PCI) of coronary artery 
disease patients with either balloon angioplasty or stent implantation is the restenosis 
of the treated lesions, that leads to recurrence of symptoms and worsening of quality 
of life. Restenosis is a typical healing process to the vessel trauma produced during 
the transluminal procedure of angioplasty and consists of elastic recoil of the dilated 
artery and neo-intimal proliferation, which is a biological response to the mechanical 
injury. The rate of post-PCI restenosis varies from less than 5% to over 50% depending 
on the different clinical and anatomical features of patients treated.
Drug eluting stents associate an anti-proliferative drug to prevent excessive neo-
intimal formation, a drug delivery system to release the active drug at a specific rate 
and a stent to carry both the drug and the drug delivery system and to act as a mechani-
cal scaffolding device. Up to date extensive investigation of DES in clinical practice 
includes the sirolimus-eluting stents (SES CYPHER™) and the paclitaxel-eluting 
stents (PES TAXUS™). Implantation of these devices, compared with bare metal 
stents (BMS), has led to a dramatic decrease of post PCI restenosis rate in the first 
pivotal clinical trials as well as the large randomized studies performed throughout 
the world [1-6], indicating that the risk of restenosis can be reduced by 49% to 81% 
when drug-eluting stents are used to treat new and relatively non-complex lesions 
included in these trials. In every day “real world” practice also, compared with an 
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historical control trial ARTS [7], DES effectiveness over BMS 
has been definitely documented according to RESEARCH 
registry data [8]. More recently data from the T-SEARCH 
registry [9] and the ARTS II study [10] which included patient 
subsets with more complex and higher restenosis-risk lesions, 
confirmed the improved results of DES over BMS and showed 
for the first time non inferiority of DES PCI to coronary artery 
bypass grafting (CABG) surgery in the treatment of patients 
with multivessel coronary artery disease. As a result, from 
the clinical point of view, introduction of effective DES al-
lowed physicians to treat patients with more complex and 
high restenosis-risk lesions, such as diabetics or patients with 
long lesions in relatively small vessels, proximal location and 
total occlusions, who were treated before with CABG. This 
circumstance translated into a great increase in the quality 
of life of these patients.
C O S T  O F  D E S
However, although clinical benefits of DES usage are in-
creasingly evident, important concerns about their cost have 
been raised in the medical community. The increased cost of 
a DES is the final result of higher research and development 
costs of the manufacturing companies, the expenditure of 
acquisition of exclusive and valuable licenses from pharma-
ceutical companies, the need of new manufacturing facilities 
for new designs and the relative low production levels [11]. 
Generally, the price of a DES is at least three-fold higher 
than the price of a conventional BMS and most authors report 
implantation of 1.5 stents per patient treated, leading to a 
significant increase of the initial total cost of the procedure. 
According to data from Lemos et al [11], the unrestricted use 
of DES in all USA patients that currently receive standard 
BMS would cost the health system about $1.5 billion each 
year. Moreover, Greenberg et al [12] estimated that uniform 
conversion of all current standard BMS procedures to DES 
would result in an initial cost increase of about $2800 per 
patient treated. Consequently, the great economical impact 
on healthcare budget, which is associated with the extensive 
use of DES remains a crucial issue, affecting worldwide so-
cioeconomic policy.
C O S T - E F F E C T I V E  I S S U E S
Issues concerning cost-effectiveness of DES include ques-
tions about the impact of DES implantation on “hard clini-
cal” end-points such as death or reinfarction, and about the 
reduction of post-PCI restenosis rate in real world practice and 
special patient subsets. Further questions relate to the impact 
of DES on need for CABG either as a primary procedure or 
during the post-PCI follow up period, the long term effective-
ness of DES in treating coronary artery disease patients and 
both short- and long-term safety of these devices.
E F F E C T  O N  M O R T A L I T Y
The main concern arises from the fact that DES use does 
not affect mortality post PCI procedures. All the available 
data show no influence of DES implantation on mortality 
rate following the procedure, when compared to the BMS. 
Indeed, the combined analysis of the TAXUS II, IV, V, VI 
clinical trials showed no difference in survival rate during 
a follow-up period of two years between patients receiving 
TAXUS™ stents or control BMS (97.7% versus 97.6% respec-
tively). Similar pooled analysis of 4 clinical trials (SIRIUS, E 
SIRIUS, C SIRIUS and RAVEL) using CYPHER™ stents 
in 1748 patients showed again no difference in mortality 
rate, during a follow-up period of 2.5 years, between patients 
who were treated with DES or control BMS (4.1% versus 
3.0% respectively). In addition, in a meta-analysis of DES 
randomized trials, Babapulle et al showed that DES use had 
no impact on mortality or myocardial infarction (MI) rate in 
comparison to BMS [6]. On the other hand, the main effect of 
DES implantation, that is the reduction of restenosis rate, is a 
secondary outcome and up to date no study has demonstrated 
a definite link between restenosis and mortality [13], except 
one report of BMS use mostly in diabetic patients [14]. Con-
sequently, despite the clear clinical benefits, concerns remain 
on whether the additional costs associated with the reduction 
or even elimination of restenosis are worth paying.
R I S K  O F  R E S T E N O S I S
It is widely acceptable that restenosis cannot be predicted. 
Multivessel stenting and diabetes are the two main patient 
related variables increasing the possibility of restenosis. Lesion 
related variables correlated with restenosis risk are the size of 
the vessel, the lesion length and consequently the stent length, 
the minimum lumen diameter pre- and post-procedure, the 
location or the type of lesion (ostial, occlusion, bifurcation) 
and the presence of multiple stents. So, it is anticipated that in 
diabetic patients with high grade long lesions in multiple small 
size (<3.0 mm) vessels, restenosis risk is the highest.
Post-PCI restenosis rate is derived mainly from the results 
of randomized clinical trials. It is well established that DES 
usage in patients with simple and low restenosis-risk lesions 
leads to an exceptionally significant decrease of restenosis rate 
when compared to BMS [1,2,4,15-17]. When used in patients 
with more complex lesions or special conditions the results 
still remain far better but nevertheless not so favourable as in 
simple lesions [3,5,18-20]. The increased, compared to BMS, 
efficacy of DES in the treatment of daily practice patients 
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with high risk and complex lesions has been confirmed by 
the recent big registries’ results [8-10], while the comparative 
efficacy of these devices to CABG will be shown when the 
results of the on-going mega trials FREEDOM and SYNTAX 
are presented.
Long term efficacy of SES in preventing restenosis of 
the dilated lesions has been established by several studies 
[21,22]. Recently, the 2-year follow-up data of RESEARCH 
showed persistent lower rate of clinically driven target vessel 
revascularization (TVR) among patients treated with SES 
in comparison with BMS (6.4% vs 14.7% respectively) [23]. 
The long-term follow-up also of the TAXUS trials showed 
persistently increased efficacy of PES in preventing new target 
lesion revascularization (TLR) procedures and total major 
adverse cardiac events (MACE) rate.
According to ARTS II study data, patients treated with 
DES PCI present during a follow-up of 1 year similar course 
with that of patients treated surgically in the ARTS study. 
Patients of ARTS II showed 1.0% mortality rate, 1.2% new 
MI rate, 7.4% re-intervention rate and total MACE rate of 
10.4%. On the other hand, patients of the ARTS study treated 
surgically presented a mortality rate of 2.7%, 3.5% new MI 
rate, 3.7% re-intervention rate and total MACE rate of 11.6%. 
These data underscore the non inferiority of DES PCI to 
CABG, with a clinical implication of leading many patients 
and physicians to select PCI with DES implantation as the 
primary treatment option of coronary artery disease instead 
of CABG. Moreover, the decreased need for re-interventions, 
due to lower rates of restenosis and TLR among patients 
treated with DES implantation, leads definitely to a lower 
need of CABG post DES PCI compared to BMS PCI.
Stent thrombosis and other safety issues. Finally, as far 
as the safety of these devices, all the available data show no 
difference in subacute or late thrombosis rate between DES 
and standard BMS, if proper antiplatelet therapy is given. 
The reported low rate of very late thrombosis, associated es-
pecially with PES, is a unique finding necessitating long-term 
combined antiplatelet therapy at least in some special cases 
[24]. The finding of increased rate of late stent malapposi-
tion among patients treated with DES in some studies has 
not been correlated with an adverse event and so it cannot 
be counted as a safety issue. The only unsolved safety issue 
is the “late catch-up” phenomenon described by Virmani et 
al [25], that represents an inexplicable increase of restenosis 
rate between 6 and 12 months or even later with some special 
type of DES. From all the above mentioned, it is clear that 
DES are effective and safe devices in reducing (compared 
to BMS) restenosis and the need for a new revascularization 
procedure rate in about 75% of patients with coronary artery 
disease treated non surgically, without affecting mortality. 
Their use is correlated with higher procedural and initial cost 
of PCI comparing to BMS.
Analyses of cost-effectiveness. Several cost-effectiveness 
analyses have been performed to access the economic bur-
den of restenosis to the health care system. They take into 
account the frequency of clinically important restenosis and 
the additional health care costs associated with its treatment, 
which vary according to the specific patients’ population char-
acteristics under investigation and to the healthcare system 
reality where they are applied. Cohen et al [26] presented in 
2004 a cost-effectiveness analysis of the SIRIUS trial, among 
patients with complex coronary stenoses who were treated with 
CYPHER™ stents or conventional BMS. Initial hospital costs 
were increased by $2881 per patient with SES. During the 1-
year follow-up period, use of SES led to significant reduction 
in the need for repeat revascularization procedures and of the 
follow-up costs by $2571 compared to BMS. The net increase 
of 1-year cost was estimated at $309 per patient treated with 
SES. The authors concluded that the use of SES in patients 
with complex coronary stenoses appears to be reasonably cost-
effective and with the availability of new longer stents it would 
reduce total 1-year costs compared with BMS.
In another analysis of RAVEL trial, among patients 
with rather simple and low restenosis-risk lesions who were 
treated with either CYPHER™ stents or BMS, van Hout et 
al [27] showed that DES use was associated with an increase 
of initial hospital cost by €1286 per patient. However, due 
to less revascularization procedures during 1-year follow-up 
(11.1% less major adverse cardiac events-MACE) among 
patients treated with DES, the final additional one year cost 
was estimated at €166. The authors concluded that there is 
an attractive balance between costs and effects of SES in the 
treatment of single and simple native de novo coronary lesions, 
while cost effectiveness of DES in complex lesions remains 
to be determined. Nevertheless, it has to be emphasized that 
in this trial the cost of purchase of both SES and BMS used 
was much cheaper than the other trials.
Greenberg et al [12] showed that treatment with DES 
could be cost-effective for patients with estimated re-inter-
vention likelihood greater than 12% and even cost saving for 
patients with estimated re-intervention likelihood greater 
than 20%, especially if the therapeutic alternative for these 
patients is the invasive and expensive surgery. Finally, Serruys 
[28] in the cost-effectiveness analysis of RESEARCH and 
T-SEARCH registries estimated the cost-effective price of 
DES to be around €1200-1500, instead of the current price 
of €2500-3300.
C O N C L U S I O N
In summary, DES use during PCI substantially reduces 
restenosis of the treated lesions and repeat revascularization 
procedures, resulting in a high demand of these devices by 
both physicians and patients and in an increase of health care 
costs. The cost-effectiveness of DES depends on the target 
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population features and the specific treatment comparator 
(BMS, CABG or medical therapy). According to the data of 
economic analyses and clinical trials, DES will be reasonably 
cost-effective for a great percentage of patients and even cost 
saving for the subgroup of patients who are at high risk of 
clinical restenosis with the conventional PCI techniques. It 
has to be mentioned that in the past worthy techniques such 
as balloon angioplasty was introduced with a procedural cost 
of $4300 and coronary stenting was performed at a cost of 
$4400 [11]. The main limitation of wider application of DES 
in the daily interventional practice and higher penetration rate 
of these devices in non surgical treatment of coronary artery 
disease is, for the moment, their high price. In the future, lower 
costs of DES should render this technology cost saving for a 
larger group of PCI patients, broadening the target population 
even for the treatment of vulnerable plaques, which is the next 
hot spot of interventional cardiology.
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